Highly effective generic adjuvant systems for orphan or poverty-related vaccines

被引：25

作者：

Rao, Mangala ^{[1
]}

Peachman, Kristina K. ^{[1
,2
]}

Li, Qin ^{[3
]}

Matyas, Gary R. ^{[1
]}

Shivachandra, Sathish B. ^{[3
]}

Borschel, Richard ^{[4
]}

Morthole, Venee I. ^{[5
]}

Fernandez-Prada, Carmen ^{[4
]}

Alving, Carl R. ^{[1
]}

Rao, Venigalla B. ^{[3
]}

机构：

[1] Walter Reed Army Inst Res, US Mil HIV Res Program, Div Retrovirol, Rockville, MD 20850 USA

[2] Henry M Jackson Fdn Adv Mil Med, Rockville, MD USA

[3] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA

[4] Walter Reed Army Inst Res, Div Bacterial & Rickettsial Dis, Silver Spring, MD USA

[5] Walter Reed Army Inst Res, Div Pathol, Silver Spring, MD USA

来源：

VACCINE | 2011年 / 29卷 / 05期

基金：

美国国家卫生研究院;

关键词：

Adjuvants; Liposomes; Monophosphoryl lipid A; Bacteriophage T4; Anthrax; Non-human primates; ANTHRAX PROTECTIVE ANTIGEN; BACILLUS-ANTHRACIS; RHESUS MACAQUES; BACTERIOPHAGE-T4; PROTEINS; DELIVERY; DISPLAY; STRAIN;

D O I：

10.1016/j.vaccine.2010.11.049

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Safe and effective adjuvants are needed for many vaccines with limited commercial appeal, such as vaccines to infrequent (orphan) diseases or to neglected and poverty-related diseases. Here we found that three nonproprietary liposome formulations containing monophosphoryl lipid A each induced 3-fold to 5-fold increased titers of binding and neutralizing antibodies to anthrax protective antigen compared to aluminum hydroxide-adsorbed antigen in monkeys. All vaccinated monkeys were protected against lethal challenge with aerosolized Ames strain spores. Published by Elsevier Ltd.

引用

页码：873 / 877

页数：5

共 28 条

[1] Design and selection of vaccine adjuvants: animal models and human trials [J].

Alving, CR .

VACCINE, 2002, 20 :S56-S64

[2] Aluminum salts in vaccines - US perspective [J].

Baylor, NW ;

Egan, W ;

Richman, P .

VACCINE, 2002, 20 :S18-S23

[3] Anthrax vaccination strategies [J].

Cybulski, Robert J., Jr. ;

Sanz, Patrick ;

O'Brien, Alison D. .

MOLECULAR ASPECTS OF MEDICINE, 2009, 30 (06) :490-502

[4]

DARLOW HM, 1956, LANCET, V271, P476

[5] Advances in the development of next-generation anthrax vaccines [J].

Friedlander, Arthur M. ;

Little, Stephen F. .

VACCINE, 2009, 27 :D28-D32

[6] GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives [J].

Garcon, Nathalie ;

Chomez, Patrick ;

Van Mechelen, Marcelle .

EXPERT REVIEW OF VACCINES, 2007, 6 (05) :723-739

[7] Boosting Vaccine POWER [J].

Garcon, Nathalie ;

Goldman, Michel .

SCIENTIFIC AMERICAN, 2009, 301 (04) :72-79

[8] Countering anthrax: Vaccines and immunoglobulins [J].

Grabenstein, John D. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (01) :129-136

[9]

Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681

[10] Vaccine adjuvants: scientific challenges and strategic initiatives [J].

Harandi, Ali M. ;

Davies, Gwyn ;

Olesen, Ole F. .

EXPERT REVIEW OF VACCINES, 2009, 8 (03) :293-298

← 1 2 3 →